Giuseppe Ciaramella, president at Beam Therapeutics (NASDAQ: BEAM), sold 11,810 shares of the company’s common stock on April 1, 2026, at a price of $24.58 per share, producing proceeds of approximately $290,289. The transaction is recorded in an SEC filing that notes the shares were sold automatically to satisfy tax withholding obligations triggered by the vesting of restricted stock units.
Following the disposition, Ciaramella retains direct ownership of 218,406 shares of Beam Therapeutics. The filing also indicates the shares were sold pursuant to a Rule 10b5-1 trading arrangement that Ciaramella adopted on May 23, 2023.
The sale comes against a backdrop of strong share performance over the prior 12 months, with the stock having returned roughly 59% during that period. At the same time, Beam’s shares present notable volatility, reflected in a beta of 2.19 cited in the filing.
Separate valuation commentary in the filing references InvestingPro analysis, which regards the stock as appearing undervalued at current market levels and highlights that Beam’s balance sheet shows more cash than debt.
Clinical and analyst developments have provided additional context for the company’s recent market activity. Beam Therapeutics reported data from its Phase 1/2 BEACON clinical trial for a sickle cell disease treatment in The New England Journal of Medicine. That trial enrolled 31 patients, with follow-up times spanning from 0.3 to 20.4 months.
Beam also disclosed positive Phase 1/2 results for its BEAM-302 program in alpha-1 antitrypsin deficiency (AATD), identifying a 60 mg dose as the appropriate level to carry into further development. Several research firms adjusted their views and price targets following the updated BEAM-302 data.
Bernstein SocGen Group reiterated an Outperform rating on the stock with a $40.00 price target, citing the encouraging clinical readouts. Leerink Partners raised its price objective to $47 from $42 while maintaining an Outperform rating, pointing to the updated BEAM-302 Phase 1/2 data. William Blair also kept an Outperform rating, noting that the 60 mg cohort for BEAM-302 produced the highest mean serum AAT level reported clinically to date. Clear Street maintained a Buy rating and a $37.00 price target, and confirmed the 60 mg dose as the optimal choice for pivotal development of BEAM-302.
Summary of the transaction and context:
- The sale involved 11,810 shares at $24.58 per share, yielding approximately $290,289 in proceeds.
- Transaction was automatic to cover tax withholding related to vested restricted stock units and executed under a Rule 10b5-1 plan adopted May 23, 2023.
- After the sale, Ciaramella directly owns 218,406 shares.
- Market context includes a 59% one-year return for the stock and a beta of 2.19, alongside positive Phase 1/2 clinical updates and multiple analyst ratings affirming Outperform/Buy stances and adjusting price targets.
Readers should note that the SEC filing footnote describing the nature of the sale frames it as an automated tax-related disposition rather than a discretionary sale for cash or other purposes.